Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Anaptysbio (ANAB) over the last 12 years, with Q3 2025 value amounting to $29.1 million.

  • Anaptysbio's Shares Outstanding (Weighted Average) rose 66.45% to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.1 million, marking a year-over-year increase of 66.45%. This contributed to the annual value of $28.4 million for FY2024, which is 541.52% up from last year.
  • As of Q3 2025, Anaptysbio's Shares Outstanding (Weighted Average) stood at $29.1 million, which was up 66.45% from $29.7 million recorded in Q2 2025.
  • Anaptysbio's Shares Outstanding (Weighted Average)'s 5-year high stood at $30.6 million during Q1 2025, with a 5-year trough of $26.8 million in Q1 2024.
  • Over the past 5 years, Anaptysbio's median Shares Outstanding (Weighted Average) value was $27.7 million (recorded in 2022), while the average stood at $28.0 million.
  • Per our database at Business Quant, Anaptysbio's Shares Outstanding (Weighted Average) crashed by 442.22% in 2023 and then skyrocketed by 1433.9% in 2025.
  • Anaptysbio's Shares Outstanding (Weighted Average) (Quarter) stood at $27.4 million in 2021, then rose by 2.68% to $28.2 million in 2022, then fell by 4.41% to $26.9 million in 2023, then increased by 5.42% to $28.4 million in 2024, then grew by 2.48% to $29.1 million in 2025.
  • Its last three reported values are $29.1 million in Q3 2025, $29.7 million for Q2 2025, and $30.6 million during Q1 2025.